Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Santersus AG logo — We are an Innovative company looking to revolutionize the hu...

Santersus AG

We are an Innovative company looking to revolutionize the human immune and inflammatory response to serious diseases.

Founded 2017 Switzerland Zurich, Switzerland 6 employees Health Care, Manufacturing

General Information

Company Name Santersus AG
Founded Year 2017
Location Switzerland Zurich, Switzerland +1
Employees 6
Industries Health Care, Manufacturing
Social

Get notified when Santersus AG moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Santersus AG

Santersus AG is a Swiss-based startup focused on revolutionizing the therapeutic treatment of patients in various areas through the selective extra corporeal removal of NETs and cell-free DNA from blood. The company's patented NucleoCapture apheresis device utilizes biocompatible, highly porous polymer beads conjugated with proprietary human recombinant histone H1.3 protein to achieve over 95% removal of NETs from contaminated blood in a single pass, without compromising the defensive function of neutrophils. Founded in 2017, Santersus AG operates in the Health Care and Manufacturing industries. The company has received phenomenal feedback from its diagnostic capability feasibility study, paving the way for further development and market achievement in 2021. With its innovative technology and promising results, Santersus AG presents a disruptive approach to therapeutic apheresis in critical care. The company's focus on addressing serious diseases through advanced blood purification methods positions it as a compelling player in the healthcare sector. While specific investment details are not available, Santersus AG's unique strategy and potential for market impact make it an intriguing prospect for venture capital firms seeking opportunities in the healthcare and biotechnology space.

Taxonomy: Immunotherapy, Blood purification, Therapeutic apheresis, NETs, Neutrophil Extracellular Traps, Autoimmunity, Oncology, Diagnostics, Liquid Biopsy, DNA extraction, Cell-free DNA, Medical technology, Biocompatible materials, Innate immune system, Biomedical devices

No funding data available for Santersus AG yet.

Get notified when Santersus AG raises funding

Santersus AG Alternatives & Competitors

Santersus AG vs
Leadartis
Leadartis Spain

Molecular Engineering for Health

Seed
7 employees
Biopharma, Biotechnology
Santersus AG vs
Bio Basic Inc.
Bio Basic Inc. Canada

Quality-Affordable Research

55 employees
Biotechnology, Life Sciences
Santersus AG vs
DyNAbind GmbH
DyNAbind GmbH Germany

Accelerating Drug Discovery

Seed
8 employees
Biopharma, Biotechnology

FAQ About Santersus AG

We are an Innovative company looking to revolutionize the human immune and inflammatory response to serious diseases.
Santersus AG was founded in 2017.
Santersus AG is headquartered in Zurich, Switzerland.
Santersus AG operates in the following industries: Health Care, Manufacturing.
Santersus AG has approximately 6 employees.
Top alternatives and competitors to Santersus AG include Leadartis, Bio Basic Inc., DyNAbind GmbH, PrecisionMed, Kangstem Biotech Co., Ltd.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Santersus AG and Leadartis are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Santersus AG and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy